Erratum
After publication of this work [1], we noted that we inadvertently failed to include the complete list of all co-authors. In this erratum we rectify these mistakes. The full list of authors and the updated Authors Contributions section are reported below. We apologize for any inconvenience this oversight may have caused.
Corrected Authors’ List:
Anastasia S. Proskurina, Tatiana S. Gvozdeva, Ekaterina A. Alyamkina, Evgenia V. Dolgova, Konstantin E. Orishchenko, Valeriy P. Nikolin, Nelly A. Popova, Sergey V. Sidorov, Elena R. Chernykh, Alexandr A. Ostanin, Olga Y. Leplina, Victoria V. Dvornichenko, Dmitriy M. Ponomarenko, Galina S. Soldatova, Nikolay A. Varaksin, Tatiana G. Ryabicheva, Peter N. Uchakin, Stanislav N. Zagrebelniy, Vladimir A. Rogachev, Sergey S. Bogachev, and Mikhail A. Shurdov.
References
Proskurina AS, Gvozdeva TS, Alyamkina EA, Dolgova EV, Orishchenko KE, Nikolin VP, et al. Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer. BMC Cancer. 2015;15:122. doi:10.1186/s12885-015-1142-z.
Author information
Authors and Affiliations
Corresponding author
Additional information
Authors’ contributions
ASP performed the analysis, interpreted the data, and drafted the manuscript. TSG carried out clinical work with patients and drafted the manuscript. EAA carried out the molecular studies. EVD carried out the molecular studies. KEO performed the design of the study and provide the technical conditions for perform works. VPN performed the analysis and interpreted the data. NAP participated in the design of the study. SVS carried out clinical work with patients and participated in study design. ERC participated in the design of the study. AAO performed the analysis and interpreted the data. OYL carried out experiments to estimate the adaptive immunity induction. VVD helped in the data interpretation. DMP carried out clinical work with patients. GSS helped in the data interpretation. NAV, TGR and PNU carried out cytokine analysis. SNZ participated in the design of the study. VAR carried out production of DNA preparation. SSB conceived the study, participated in its design, and coordinated and drafted the manuscript. MAS participated in the study design and coordination. All authors read and approved the final manuscript.
The online version of the original article can be found under doi:10.1186/s12885-015-1142-z.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Proskurina, A.S., Gvozdeva, T.S., Alyamkina, E.A. et al. Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer. BMC Cancer 16, 117 (2016). https://doi.org/10.1186/s12885-016-2163-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12885-016-2163-y